Document is current
Any future updates will be listed below
-
Authors
Lavia, Carlo
Mecê, Pedro https://orcid.org/0000-0001-7685-3999
Nassisi, Marco https://orcid.org/0000-0002-9354-9005
Bonnin, Sophie
Marie-Louise, Jennifer
Couturier, Aude
Erginay, Ali
Tadayoni, Ramin
Gaudric, Alain https://orcid.org/0000-0002-2486-4722
- License Information
-
More Information
Article History
Received: 30 September 2019
Accepted: 9 January 2020
First Online: 30 January 2020
Competing interests
: Dr. Bonnin is a board member for Allergan (Ireland) and Bayer HealthCare (Germany). Dr. Couturier is a board member for Allergan (Ireland), Bayer HealthCare (Germany) and Novartis Pharma (Switzerland). Dr. Erginay is a board member for Allergan (Ireland) and Bayer HealthCare (Germany). Pr Tadayoni is Board member for Alcon, Switzerland; Novartis, Switzerland; Roche, Switzerland; Allergan, USA; Bausch and Lomb, USA; Genentech, USA; Pfizer, USA; Alimera, USA; Bayer, Germany; FCI-Zeiss, France; Thrombogenics, Belgium and consultant for Allergan, USA; DORC, Netherlands; Alcon, Switzerland; Novartis, Switzerland; Bausch and Lomb, USA; FCI-Zeiss, France; Thrombogenics, Belgium), has received lecture fees (Alcon, USA; Bausch and Lomb, USA; Novartis, Switzerland; Allergan, USA; Bayer, Germany; Alimera, USA), educational presentation fees (Bausch and Lomb, USA; Novartis, Switzerland; Zeiss, Germany; Sony, Japan; Alcon, Switzerland; Allergan, USA), meeting expenses (Novartis, Switzerland; Alcon, Switzerland; Allergan, USA; Bausch and Lomb, USA; Pfizer, USA; Bayer, Germany; DORC, Netherlands; Alimera, USA). A. Gaudric has received travel grants from Novartis Pharma and Bayer HealthCare, honoraria from Thrombogenics for participation in a data monitoring committee and honoraria for an educational project from Novartis Pharma. Dr. Lavia, Mecê, Nassisi and Marie-Louise declare no potential conflict of interest.
